SCHEMBL7147047

SCHEMBL7147047

CCOc1nc(N)nc(-c2ccco2)c1Br

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 13/20 0.47
ADORA1 P30542 10/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
RECQL P46063 1/20 0.44
DHFR P00374 1/20 0.42
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
ADORA2B P29275 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CCNA1 P78396 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7147864 0.88 KDM4E (0.45) ADORA2AADORA1NPC1RAB9ADHFR
SCHEMBL7151592 0.86 ADORA2A (0.44) ADORA2AADORA1DHFRADORA2B
SCHEMBL7142558 0.84 ADORA2A (0.46) ADORA2AADORA1NPC1RAB9ARECQL
SCHEMBL7146875 0.84 ADORA2A (0.43) ADORA2AADORA1DHFRCCNA2CDK2
SCHEMBL7144843 0.83 ADORA2A (0.49) ADORA2AADORA1ADORA2BTSHRCCNA2
SCHEMBL7149986 0.81 ADORA2A (0.51) ADORA2AADORA1ADORA2BSMN1; SMN2CCNA2
SCHEMBL1553903 0.81 ADORA2A (0.60) ADORA2AADORA1RECQLDHFRKDM4E
SCHEMBL5046844 0.81 ADORA1 (0.60) ADORA2AADORA1KDM4EGAAHPGD
SCHEMBL5046627 0.80 ADORA2A (0.53) ADORA2AADORA1ADORA2B
SCHEMBL5046435 0.80 ADORA2A (0.51) ADORA2AADORA1RECQLKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885NPC1 2213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.